Veterinary Oncology MarketSize, Share & Industry Analysis, 2026-2034By Therapy ModalityBy Cancer IndicationBy Tumor ClassificationBy Animal TypeBy Route of AdministrationBy Treatment Setting / End UserBy Development / Regulatory StageBy Diagnostic & Monitoring ModalityBy Treatment Intent / Care Pathway StageBy Distribution Channel

Veterinary oncology covers the diagnosis, staging and treatment of cancer in companion and performance animals, spanning surgical removal of tumors, injectable and oral chemotherapy protocols, external-beam radiation therapy, newer targeted small-molecule and immunotherapy agents, and the diagnostic tools used to detect and monitor disease, including histopathology, diagnostic imaging, liquid biopsy and molecular tumor profiling. Buyers are veterinary referral and specialty oncology centers, general practice clinics that refer complex cases onward, academic teaching hospitals, and the corporate multi-site hospital groups that increasingly build oncology service lines across their networks. Treatment decisions are shaped by the animal's tumor type and stage, the owner's willingness and ability to pay for advanced care, and whether the intent is curative, palliative or long-term surveillance.

The global veterinary oncology market stood at USD 1820 million in 2025. A forecast-period rate of 12.14% takes it to USD 5100 million by 2034, and the study reports every year in between, passing USD 1160 million in 2020, USD 1670 million in 2024, USD 2040 million in 2026 and USD 3230 million in 2030.

32% of 2025 revenue sits in Chemotherapy, worth USD 582 million and rising to USD 1224 million at 24% by 2034, the largest therapy modality line in both years. Growth is fastest in Immunotherapy at 20.65% and slowest in Chemotherapy at 8.55%. Targeted Small-Molecule Therapy and Immunotherapy take share over the period; Surgical Oncology, Chemotherapy, Radiation Therapy and Other Therapies give it up while still growing in absolute terms.

Cut by cancer indication, the largest line is Lymphoma: 24% of 2025 revenue, worth USD 437 million, and 22% at USD 1122 million by 2034. Hemangiosarcoma grows faster at 16.4% against 11.05%, moving from 5% of revenue to 7% by 2034. Both this axis and the therapy modality one divide the same revenue, which is why they are alternative views, not components.

Geographically, 45% of 2025 revenue sits in North America (USD 819 million rising to USD 2142 million) ahead of Europe at 28% and USD 510 million. Middle East and Africa is smallest, at 5%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, six therapy modality lines and ten segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies, short of a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• Revenue grows from USD 1820 million in 2025 to USD 5100 million in 2034, a compound annual rate of 12.14%, having reached USD 1670 million in 2024 from USD 1160 million in 2020.
• 32% of 2025 revenue sits in Chemotherapy (USD 582 million) and it remains the largest therapy modality line in 2034 at USD 1224 million and 24%.
• Fastest growth on the therapy modality axis belongs to Immunotherapy: 20.65% a year, USD 127 million to USD 714 million, and a share moving from 7% to 14%.
• Scenario range for 2034 runs from USD 4340 million in the bear case to USD 5870 million in the bull case, against a base-case USD 5100 million, the spread a plan built on this forecast has to absorb.
• North America holds 45% of global revenue in 2025 at USD 819 million, the largest of the five regions tracked, and reaches USD 2142 million by 2034.
• The United States accounts for 82% of North America in the base year, worth USD 672 million in 2025 and reaching USD 1756 million by 2034, the worked country example carried through that region's chapters.
• Every line on all ten segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three movements define the forecast period in the global veterinary oncology market: how the therapy modality mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

The therapy modality mix tilts toward Immunotherapy. 20.65% against 8.55%: that gap, between Immunotherapy and Chemotherapy, is the largest on the therapy modality axis. Immunotherapy takes its share of revenue from 7% to 14% while Chemotherapy gives up ground, from 32% to 24%. Neither contracts: USD 127 million becomes USD 714 million, USD 582 million becomes USD 1224 million. What the spread decides is which of them a supplier's revenue is exposed to.

The regional balance moves. Asia Pacific moves from 16% of revenue in 2025 to 21% in 2034, worth USD 291 million rising to USD 1071 million; Latin America moves from 6% of revenue in 2025 to 6.5% in 2034, worth USD 109 million rising to USD 332 million. The remaining regions grow in absolute terms while giving up share: North America at 45% moving to 42%, Europe at 28% moving to 26%, Middle East and Africa at 5% moving to 4.5%. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Fifteen years without a discontinuity. The market moves through USD 1160 million in 2020, USD 1670 million in 2024, USD 1820 million in 2025, USD 2040 million in 2026, USD 3230 million in 2030 and USD 5100 million in 2034. No year breaks the trajectory, and the 12.14% forecast rate compares with 9.43% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the therapy modality and regional axes, not by the headline rate.

Growth is concentrated in Immunotherapy

Growth in the global veterinary oncology market comes from three measurable sources over 2026-2034: the market's own compounding at 12.14%, the share gained by faster-growing therapy modality lines, and expansion in the regions taking a larger part of global revenue.

The bear case and what drives it

Where the forecast could be beaten

Revenue is concentrated in Chemotherapy

USD 819 million of 2025 revenue is generated in North America, 45% of the global veterinary oncology market and reaches USD 2142 million by 2034. It is a dominant region on this axis, first by revenue throughout the period.

By 2034 the share stands at 42%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Chemotherapy largest at 32% of 2025 revenue, Immunotherapy fastest at 20.65%. Per-axis and per-country detail for North America sits in the full report.

The United States is the largest market within North America, generating USD 672 million in 2025 and projected to reach USD 1756 million by 2034. At 82% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 819 million in 2025 and USD 2142 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

the United States buys along the same lines as the market globally; Chemotherapy first at 32% of 2025 revenue and 24% in 2034, Immunotherapy fastest at 20.65% on a share moving from 7% to 14%. Its 82% weight in North America means those movements carry straight into the regional totals. The full report reports the United States by therapy modality separately.

In the United States veterinary oncology products are regulated under a split structure. Chemotherapeutic and targeted small molecule drugs are reviewed by the Food and Drug Administration's Center for Veterinary Medicine as new animal drugs, following the safety, efficacy, and manufacturing review required under the Federal Food, Drug, and Cosmetic Act, with a conditional approval route available for a product addressing a serious condition in a companion animal while full effectiveness data is still being generated. Therapeutic cancer vaccines and other veterinary biologics instead fall under the Department of Agriculture's Center for Veterinary Biologics, which issues a product license before a vaccine reaches the market. Labelling under either pathway must state dosage, indications, and warnings a treating veterinarian can act on directly.

The suppliers tracked in this study (Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim Animal Health, Vetoquinol S.A., Anivive Lifesciences, Inc., IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, PetDx, One Health Company (FidoCure / Vidium Animal Health), ELIAS Animal Health, Vetigenics, Inc., Torigen Pharmaceuticals, Inc., LEAH Labs, Inc., Esco Aster Pte Ltd, Elekta AB, Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, PetCure Oncology, Hallmarq Veterinary Imaging Limited, VCA Animal Hospitals (Mars Veterinary Health) and IVC Evidensia) compete in the United States across the therapy modality lines above. Two different problems sit on the same axis: holding Chemotherapy at 32% of 2025 revenue, and taking Immunotherapy while it grows at 20.65%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

8.08% of global revenue is generated in Canada; USD 147 million in 2025, reaching USD 386 million in 2034, and 18% of North America.

USD 510 million of 2025 revenue is generated in Europe, 28% of the global veterinary oncology market and reaches USD 1326 million by 2034. It is a leading region on this axis, second by revenue throughout the period.

Its share moves to 26% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Chemotherapy leads here as it does globally, at 32% of 2025 revenue, and Immunotherapy again grows fastest at 20.65%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

The largest single market in Europe is Germany, at USD 194 million in 2025 and USD 504 million in 2034. It accounts for 38% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 510 million in 2025 and USD 1326 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Germany buys along the same lines as the market globally; Chemotherapy first at 32% of 2025 revenue and 24% in 2034, Immunotherapy fastest at 20.65% on a share moving from 7% to 14%. Its 38% weight in Europe means those movements carry straight into the regional totals. Germany carries its own therapy modality breakdown in the full report.

In Germany, veterinary oncology products are governed by the European Union framework for veterinary medicinal products, administered nationally through the Federal Office of Consumer Protection and Food Safety, known as the BVL. A chemotherapeutic or biological product intended for companion animal cancer treatment can be authorised either through this national route or through a centralised assessment carried out by the European Medicines Agency's Committee for Veterinary Medicinal Products, whose opinion then applies across the bloc. Either path requires demonstrated quality, safety and efficacy before a marketing authorisation is granted, alongside compliance with Good Manufacturing Practice standards at the site of production. Product labelling and the accompanying package leaflet must be presented in German and must set out species, indication, dosage and withdrawal information clearly enough for a prescribing veterinarian to follow without ambiguity.

Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim Animal Health, Vetoquinol S.A., Anivive Lifesciences, Inc., IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, PetDx, One Health Company (FidoCure / Vidium Animal Health), ELIAS Animal Health, Vetigenics, Inc., Torigen Pharmaceuticals, Inc., LEAH Labs, Inc., Esco Aster Pte Ltd, Elekta AB, Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, PetCure Oncology, Hallmarq Veterinary Imaging Limited, VCA Animal Hospitals (Mars Veterinary Health) and IVC Evidensia are the suppliers covered in Germany. Two different problems sit on the same axis: holding Chemotherapy at 32% of 2025 revenue, and taking Immunotherapy while it grows at 20.65%. The commercial size of that position is USD 510 million in 2025 and USD 1326 million by 2034, 28% of the global total in the base year.

8.13% of global revenue is generated in the United Kingdom; USD 148 million in 2025, reaching USD 385 million in 2034, and 29% of Europe.

Within Europe, France accounts for 19% of regional revenue and 5.33% of the global total, worth USD 97 million in 2025 and USD 252 million by 2034.

Asia Pacific holds 16% of the global veterinary oncology market in 2025, worth USD 291 million on the way to USD 1071 million by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 21%, so the region grows faster than the market's 12.14% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The therapy modality mix reported at global level applies here, with Chemotherapy the largest line at 32% of 2025 revenue and Immunotherapy the fastest-growing at 20.65%. Asia Pacific is reported axis by axis and country by country in the full study.

Japan is the largest market within Asia Pacific, generating USD 102 million in 2025 and projected to reach USD 343 million by 2034. 35% of the region in the base year makes it the largest market here without making it the region. Set against USD 291 million and USD 1071 million for the region, it is why this market, and not a smaller one, is the one reported in full.

The therapy modality pattern in Japan is the global one: 32% of 2025 revenue in Chemotherapy, 24% by 2034, against 20.65% growth in Immunotherapy taking it from 7% to 14%. Because the country carries 35% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by therapy modality for Japan is reported separately in the full report.

In Japan, veterinary oncology drugs and biologics are regulated by the Ministry of Agriculture, Forestry and Fisheries under the Act on Safety Assurance of Veterinary Products. Before a chemotherapeutic agent, targeted therapy or cancer vaccine intended for companion animals can be marketed, its safety and efficacy data are assessed by the National Veterinary Assay Laboratory, which conducts the technical review underpinning the ministry's approval decision. Manufacturing sites must meet Good Manufacturing Practice standards recognised under this framework, and post-approval surveillance obligations apply once a product reaches veterinary practice. Labelling must be presented in Japanese, stating the approved indication, dosage by species and any restriction on use, so that a prescribing veterinarian is not left to interpret imported packaging written for a different market.

In Japan the field is Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim Animal Health, Vetoquinol S.A., Anivive Lifesciences, Inc., IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, PetDx, One Health Company (FidoCure / Vidium Animal Health), ELIAS Animal Health, Vetigenics, Inc., Torigen Pharmaceuticals, Inc., LEAH Labs, Inc., Esco Aster Pte Ltd, Elekta AB, Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, PetCure Oncology, Hallmarq Veterinary Imaging Limited, VCA Animal Hospitals (Mars Veterinary Health) and IVC Evidensia. Volume sits in Chemotherapy at 32% of 2025 revenue; movement sits in Immunotherapy at 20.65% growth. The commercial size of that position is USD 291 million in 2025 and USD 1071 million by 2034, 16% of the global total in the base year.

China is sized at USD 87 million in 2025, rising to USD 375 million by 2034; 4.78% of global revenue and 30% of Asia Pacific. It is reported separately from Japan across every segmentation axis in the full report.

3.19% of global revenue is generated in Australia; USD 58 million in 2025, reaching USD 193 million in 2034, and 20% of Asia Pacific.

In Latin America, 6% of global revenue puts 2025 at USD 109 million with USD 332 million projected for 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

By 2034 the share has moved up to 6.5%, on growth above the market's own 12.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Within the region the therapy modality split tracks the global one; 32% of 2025 revenue in Chemotherapy, fastest growth of 20.65% in Immunotherapy. Per-axis and per-country detail for Latin America sits in the full report.

USD 60 million of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 183 million by 2034. Its 55% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 109 million in 2025 and USD 332 million in 2034, it is the country the full report breaks out in detail.

Brazil buys along the same lines as the market globally; Chemotherapy first at 32% of 2025 revenue and 24% in 2034, Immunotherapy fastest at 20.65% on a share moving from 7% to 14%. Its 55% weight in Latin America means those movements carry straight into the regional totals. Revenue by therapy modality for Brazil is reported separately in the full report.

In Brazil, veterinary oncology products are regulated by the Ministry of Agriculture, Livestock and Supply, which registers veterinary pharmaceuticals and biologics before they may be sold. A chemotherapeutic agent or cancer vaccine intended for companion animal use must be registered with the ministry's animal health directorate, with supporting data on composition, safety and therapeutic efficacy reviewed before registration is granted. Manufacturing facilities, whether domestic or foreign, must hold a certificate of good manufacturing practice recognised by the ministry, and importers must maintain local representation for regulatory correspondence. Labelling must be in Portuguese and must set out the approved indication, target species, dosage and any withdrawal period, matching the terms under which the product was registered.

The suppliers tracked in this study (Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim Animal Health, Vetoquinol S.A., Anivive Lifesciences, Inc., IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, PetDx, One Health Company (FidoCure / Vidium Animal Health), ELIAS Animal Health, Vetigenics, Inc., Torigen Pharmaceuticals, Inc., LEAH Labs, Inc., Esco Aster Pte Ltd, Elekta AB, Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, PetCure Oncology, Hallmarq Veterinary Imaging Limited, VCA Animal Hospitals (Mars Veterinary Health) and IVC Evidensia) compete in Brazil across the therapy modality lines above. Two different problems sit on the same axis: holding Chemotherapy at 32% of 2025 revenue, and taking Immunotherapy while it grows at 20.65%. The commercial size of that position is USD 109 million in 2025 and USD 332 million by 2034, 6% of the global total in the base year.

Within Latin America, Mexico accounts for 30% of regional revenue and 1.81% of the global total, worth USD 33 million in 2025 and USD 100 million by 2034.

USD 91 million of 2025 revenue is generated in Middle East and Africa, 5% of the global veterinary oncology market on the way to USD 229 million by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

4.5% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Chemotherapy largest at 32% of 2025 revenue, Immunotherapy fastest at 20.65%. Middle East and Africa is reported axis by axis and country by country in the full study.

40% of Middle East and Africa's base-year revenue comes from the United Arab Emirates; USD 36 million, rising to USD 92 million by 2034. At 40% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 91 million in 2025 and USD 229 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in the United Arab Emirates follows the therapy modality mix reported at global level: Chemotherapy is the largest line at 32% of 2025 revenue, moving to 24% by 2034, while Immunotherapy grows fastest at 20.65% and takes its share from 7% to 14%. With 40% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports the United Arab Emirates by therapy modality separately.

In the United Arab Emirates, veterinary oncology products fall under the federal authority of the Ministry of Climate Change and Environment, which registers veterinary medicinal products and biologics before they can be imported or sold. A chemotherapeutic drug or cancer vaccine intended for companion animal treatment must be registered centrally, with supporting dossiers on composition, safety and efficacy assessed before an import permit is issued for each consignment. Distribution is restricted to licensed veterinary pharmacies and clinics, and a registered local agent must be maintained by any foreign manufacturer seeking market access. Labelling must appear in Arabic alongside the original language, stating the approved indication, dosage, species and storage conditions clearly for the treating veterinarian.

The suppliers tracked in this study (Zoetis Inc., Elanco Animal Health Incorporated, Merck Animal Health (Merck & Co., Inc.), Boehringer Ingelheim Animal Health, Vetoquinol S.A., Anivive Lifesciences, Inc., IDEXX Laboratories, Inc., Antech Diagnostics (Mars, Incorporated), Heska Corporation, PetDx, One Health Company (FidoCure / Vidium Animal Health), ELIAS Animal Health, Vetigenics, Inc., Torigen Pharmaceuticals, Inc., LEAH Labs, Inc., Esco Aster Pte Ltd, Elekta AB, Siemens Healthineers (Varian Medical Systems), Accuray Incorporated, PetCure Oncology, Hallmarq Veterinary Imaging Limited, VCA Animal Hospitals (Mars Veterinary Health) and IVC Evidensia) compete in the United Arab Emirates across the therapy modality lines above. Volume sits in Chemotherapy at 32% of 2025 revenue; movement sits in Immunotherapy at 20.65% growth. Weighting toward Middle East and Africa means competing for 5% of 2025 global revenue, a base of USD 91 million moving to USD 229 million across the forecast period.

1.48% of global revenue is generated in South Africa; USD 27 million in 2025, reaching USD 69 million in 2034, and 30% of Middle East and Africa.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Therapy Modality, Cancer Indication, Tumor Classification, Animal Type, Route of Administration, Treatment Setting / End User, Development / Regulatory Stage, Diagnostic & Monitoring Modality, Treatment Intent / Care Pathway Stage, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.